Name

Grand Life Sciences

Legal name

远大医学营养科学（武汉）有限公司

Website

https://dazy.cn

Company type

Private

Founded year

2003

Operating status

Operating

Ownership category

akta.pro rank

Product category

Injectable Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

akta.pro secondary industry

Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)

Keywords

• Injectable pharmaceuticals
• Lipid microsphere drug delivery
• Perioperative analgesic injection
• Active pharmaceutical ingredients
• GMP-certified pharmaceutical manufacturing

Headquarters

HQ city

Wuhan

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Pharmaceutical Product Manufacturing and Sales: Core revenue stream from development, manufacturing, and sales of pharmaceutical products including injectable drugs (安瓿注射剂, 大输液), active pharmaceutical ingredients (原料药), and oral preparations (口服乳剂). Products are sold through channel partners and direct sales teams to hospitals and medical institutions across China. Revenue supported by national volume-based procurement (集中带量采购/VBP) contracts and commercial market sales.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Grand Life Sciences is a high-tech pharmaceutical manufacturer that integrates drug R&D, production, and sales of injectable medications, active pharmaceutical ingredients, and oral preparations. Its core commercial products are Flurbiprofen Axetil Injection (Anfu®), a lipid microsphere-based targeted analgesic for post-operative and cancer pain, and Simethicone Emulsion (Anboshi®) for gastrointestinal applications. The company operates an 80,000 sqm GMP-certified manufacturing complex in Wuhan covering large-volume infusions, small-volume injections, freeze-drying, and API production, and distributes products to Chinese hospitals through national VBP procurement and provincial distribution partners.

Product overview

Grand Life Sciences (远大医学营养科学（武汉）有限公司) is a high-tech pharmaceutical company integrating R&D, manufacturing, and sales. The company operates as a subsidiary of China Yuanda Group, specializing in medical nutrition and advanced injectable formulations. Its core products include 氟比洛芬酯注射液（安抚®）for pain management and 西甲硅油乳剂（安博士®）for gastrointestinal applications. The company has developed proprietary technology platforms including lipid microsphere carrier drug injection technology and high-activity polysaccharide drug development. Manufacturing capabilities include freeze-dried injection lines, large volume infusion production, quality control laboratories, and API production under GMP certification. The product portfolio is supported by an academician expert workstation and a 30+ person R&D team.

Differentiator

Problem solved

Functional benefit

Brands

• 安抚®: 氟比洛芬酯注射液，用于术后及癌症病人的靶向镇痛药物，是公司历经十余年研发的首仿产品
• 安博士®

Products and services

• Flurbiprofen Axetil Injection (Anfu® 安扶®) A lipid microsphere-based targeted analgesic injection used by hospitals for post-operative and cancer pain management. It is the first domestically manufactured nano-injection product approved in China and the first generic to break Japanese technology monopoly. Contains flurbiprofen axetil as active pharmaceutical ingredient.
• Simethicone Emulsion (Anboshi® 安博士®) A simethicone-based emulsion injection product used for gastrointestinal applications as an auxiliary medication for gastrointestinal examination preparation. Launched in 2022 for diagnostic and therapeutic purposes.
• Alanylglutamine API (丙氨酰谷氨酰胺原料药) Active pharmaceutical ingredient for alanylglutamine injection, produced under GMP certification. The company manufactures both the API and finished dosage forms. Supplied to domestic and international pharmaceutical manufacturers.

Quantifiable outcome

• Flurbiprofen Axetil Injection reduced imported drug price by ~70% upon market entry, saving over 1 billion RMB annually for national medical insurance
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

14 partnerships are on record, tiered core and minor.

• 辽宁远大诺康生物制药有限公司 (Liaoning Grand Nucam Biopharmaceutical Co., Ltd.)coreStrategic or Co-development Partner · 1 January 2021In January 2020, the company underwent merger and restructuring, joining China Grand Group's pharmaceutical health segment through integration with Liaoning Grand Nucam. This provided access to Grand Group's broader resources, sales networks, and R&D capabilities. The company became part of Grand Nucam's 'Greater Wuhan' pharmaceutical platform. In August 2021, the company name officially changed from 武汉大安制药有限公司 to 远大生命科学（武汉）有限公司.
• 华润湖北医药有限公司 (China Resources Hubei Pharmaceutical Co., Ltd.)coreChannel Partner/ Reseller/ Distributor · 1 January 2018Key strategic distribution partner for安抚® (Flurbiprofen Axetil Injection) in Hubei province. One of China's largest state-owned pharmaceutical distribution companies.
• 上海乐明医药 (Shanghai Laming Pharmaceutical)coreChannel Partner/ Reseller/ Distributor · 1 January 2018Strategic commercial partner for安抚® product marketing and distribution, present at national launch events and regional promotions.
• 北京盛世康源医药 (Beijing Shengshi Kangyuan Pharmaceutical)coreChannel Partner/ Reseller/ Distributor · 1 January 2018Strategic commercial partner for安抚® product in the Beijing region market.
• 广东康美药业 (Guangdong Kangmei Pharmaceutical)coreChannel Partner/ Reseller/ Distributor · 1 January 2018Key distribution partner for安抚® product in the Guangdong province market.
• 云南泰康医药 (Yunnan Taikang Pharmaceutical)coreChannel Partner/ Reseller/ Distributor · 1 January 2018Strategic partner in Yunnan province for pharmaceutical product distribution, actively supported regional marketing meetings.
• 合肥亿帆 (Hefei Yifan)minorChannel Partner/ Reseller/ Distributor · 1 January 2018Regional commercial partner for安抚® product distribution in Anhui province, participated in national launch event.
• 南京星鲨 (Nanjing Xingsha)minorChannel Partner/ Reseller/ Distributor · 1 January 2018Regional commercial partner for安抚® distribution in Jiangsu province.
• 河南金保康 (Henan Jinbaokang)minorChannel Partner/ Reseller/ Distributor · 1 January 2018Regional commercial partner for安抚® distribution in Henan province.
• 华中科技大学同济医学院 (HUST Tongji Medical College)coreStrategic or Co-development Partner · 1 January 2015The company is designated as a teaching base for HUST Tongji Medical College's School of Pharmacy, facilitating joint talent cultivation and academic exchange programs.
• 武汉理工大学 (Wuhan University of Technology)minorStrategic or Co-development Partner · 1 January 2015Designated as a teaching base for collaborative education programs in pharmaceutical sciences and related fields.
• 武汉轻工大学 (Wuhan Polytechnic University)minorStrategic or Co-development Partner · 1 January 2015Designated as a teaching base for collaborative education programs in pharmaceutical sciences.
• 华中科技大学 (Huazhong University of Science and Technology)coreStrategic or Co-development Partner · 1 January 2008Long-standing strategic R&D partnership with Huazhong University of Technology (HUST). Professor Chen Bangyin (陈邦银), a State Council special allowance recipient, serves as a special expert. HUST faculty collaborate on research projects including the enterprise academician expert workstation. The company is a HUST Tongji School of Pharmacy teaching base.
• 武汉大学 (Wuhan University)coreStrategic or Co-development Partner · 1 January 2008Strategic collaboration with Wuhan University. Professor Shu Jiayou (束家有), a State Council special allowance recipient, serves as a special expert and consultant. Dr. Huang Ling was appointed as a graduate student supervisor (校外兼职导师) by Wuhan University School of Pharmacy.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Mochida Pharmaceutical: Original Japanese developer of Flurbiprofen Axetil (Ropion®) whose technology monopoly Grand Life Sciences' Anfu® broke. Comparable as the originator of the same molecule and a broader specialty injectable manufacturer.
• Livzon Pharmaceutical Group: Hong Kong-listed Chinese pharmaceutical company with injectable, API, and specialty drug products. Comparable in scale and GMP-certified manufacturing for Chinese hospital markets.
• Jiangsu Hengrui Medicine: China's largest innovative pharmaceutical company with broad specialty injectable portfolio, including perioperative and oncology supportive care products. Comparable in targeting the same hospital channels and VBP procurement.
• Yangzi River Pharmaceutical: Major domestic Chinese pharmaceutical company with a broad specialty injectable and analgesic portfolio. Competes in the same hospital channels and VBP procurement framework.
• Sino Biopharmaceutical: Major Hong Kong-listed Chinese pharmaceutical company with a wide portfolio of injectable and specialty drugs. Competes in similar VBP channels and hospital formularies with comparable product breadth.

Direct peers

• CSPC Pharmaceutical Group: Hong Kong-listed Chinese pharmaceutical major that produces Flurbiprofen Axetil Injection and other injectable analgesic products, directly competing with Anfu® in the same hospital and VBP channels. Comparable in scale and product category.
• KPC Pharmaceuticals (Kunyao Group): Chinese pharmaceutical company with established injectable product portfolios including analgesics and specialty injectables. Both target hospital channels and participate in China's national VBP, making them a direct competitor in the domestic injectable space.
• Hefei Life Sciences (Hefei Yi Fan / 合肥亿帆): Distribution partner of Grand Life Sciences for Anfu® in Anhui province. Listed as a regional pharmaceutical and distribution player that intersects with the company's commercial channel and product portfolio.

Emerging players

• Nhwa Pharmaceutical (Jiangsu Nhwa): Chinese specialty pharmaceutical company focused on CNS and injectable products, with similar hospital-channel and VBP procurement participation. Comparable in operating scale and specialty injectable focus.

Others

• China Resources Pharmaceutical (Huarun): State-owned pharmaceutical distribution and manufacturing conglomerate that operates China Resources Hubei Pharmaceutical, a key Grand Life Sciences distribution partner. Relevant as both a channel partner and ecosystem participant in China's pharmaceutical supply chain.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Grand Life Sciences